Scilex Holding Company (SCLX) has issued an announcement.
Scilex Holding Company’s board has empowered its management to enhance the value of its subsidiary, Semnur Pharmaceuticals, and its prime product, SEMDEXA™, through various strategic options, including a spin-off or merger. Excitingly, on July 2, 2024, they announced a potential business combination with Denali Capital Acquisition Corp., signaling a significant move that could benefit stockholders and reshape the company’s future.
See more insights into SCLX stock on TipRanks’ Stock Analysis page.
